Novartis (NYSE:NVS)‘s stock had its “neutral” rating reissued by investment analysts at UBS Group in a report released on Monday, www.boersen-zeitung.de reports.

Other equities analysts have also issued reports about the company. Zacks Investment Research raised Novartis from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a research report on Tuesday, September 19th. Leerink Swann upped their target price on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research report on Tuesday, September 26th. Finally, Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $85.32.

Shares of Novartis (NYSE:NVS) traded up $0.98 on Monday, hitting $86.65. The company’s stock had a trading volume of 1,016,500 shares, compared to its average volume of 993,122. Novartis has a one year low of $69.53 and a one year high of $86.90. The firm has a market cap of $226,760.00, a price-to-earnings ratio of 30.84, a price-to-earnings-growth ratio of 2.38 and a beta of 0.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.04. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. During the same period in the prior year, the company posted $1.23 EPS. Novartis’s quarterly revenue was up 2.4% on a year-over-year basis. analysts anticipate that Novartis will post 4.77 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Cetera Investment Advisers bought a new position in Novartis during the 2nd quarter worth $241,000. Bartlett & Co. LLC grew its stake in Novartis by 1.6% during the 3rd quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock worth $40,614,000 after buying an additional 7,249 shares during the last quarter. Capital Bank & Trust Co grew its stake in Novartis by 5.5% during the 3rd quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after buying an additional 7,201 shares during the last quarter. Cedar Hill Associates LLC bought a new position in Novartis during the 3rd quarter worth $248,000. Finally, Steward Partners Investment Advisory LLC bought a new position in Novartis during the 3rd quarter worth $1,245,000. Institutional investors and hedge funds own 10.85% of the company’s stock.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/15/ubs-group-reaffirms-neutral-rating-for-novartis-nvs.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.